Cowen Reiterates “Buy” Rating for Amicus Therapeutics (FOLD)

Amicus Therapeutics (NASDAQ:FOLD)‘s stock had its “buy” rating reissued by equities research analysts at Cowen in a research report issued on Wednesday. They presently have a $22.00 price objective on the biopharmaceutical company’s stock. Cowen’s target price indicates a potential upside of 38.63% from the stock’s current price.

A number of other brokerages have also issued reports on FOLD. Chardan Capital restated a “buy” rating and issued a $16.50 target price (down previously from $17.50) on shares of Amicus Therapeutics in a research note on Wednesday, September 13th. Leerink Swann restated an “outperform” rating and issued a $17.00 target price (down previously from $18.00) on shares of Amicus Therapeutics in a research note on Saturday, September 16th. Robert W. Baird restated an “outperform” rating and issued a $16.00 target price on shares of Amicus Therapeutics in a research note on Monday, September 25th. Bank of America raised their target price on Amicus Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, October 4th. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. Amicus Therapeutics currently has an average rating of “Buy” and an average target price of $18.31.

Shares of Amicus Therapeutics (NASDAQ FOLD) opened at $15.87 on Wednesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22. The firm has a market capitalization of $2,640.00, a price-to-earnings ratio of -8.67 and a beta of 1.72. Amicus Therapeutics has a 52-week low of $5.07 and a 52-week high of $16.60.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). The business had revenue of $10.90 million during the quarter, compared to analyst estimates of $9.02 million. Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The firm’s revenue for the quarter was up 419.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.33) EPS. research analysts expect that Amicus Therapeutics will post -1.56 earnings per share for the current fiscal year.

In other Amicus Therapeutics news, CEO John F. Crowley sold 5,920 shares of Amicus Therapeutics stock in a transaction dated Saturday, December 29th. The stock was sold at an average price of $14.75, for a total transaction of $87,320.00. Following the completion of the transaction, the chief executive officer now owns 341,051 shares in the company, valued at approximately $5,030,502.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John F. Crowley sold 65,581 shares of Amicus Therapeutics stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $13.51, for a total value of $885,999.31. Following the transaction, the chief executive officer now owns 393,076 shares of the company’s stock, valued at approximately $5,310,456.76. The disclosure for this sale can be found here. Insiders sold a total of 718,920 shares of company stock valued at $10,263,669 in the last 90 days. 3.40% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sage Capital Advisors llc purchased a new position in shares of Amicus Therapeutics during the 3rd quarter valued at about $154,000. GSA Capital Partners LLP purchased a new position in shares of Amicus Therapeutics during the 3rd quarter valued at about $309,000. Iguana Healthcare Management LLC purchased a new position in shares of Amicus Therapeutics during the 3rd quarter valued at about $905,000. Sterling Capital Management LLC purchased a new position in shares of Amicus Therapeutics during the 3rd quarter valued at about $218,000. Finally, Neuberger Berman Group LLC purchased a new position in shares of Amicus Therapeutics during the 3rd quarter valued at about $196,000.

TRADEMARK VIOLATION WARNING: This news story was published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.com-unik.info/2018/01/12/cowen-reiterates-buy-rating-for-amicus-therapeutics-fold.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit